Skip to main content

Investors

Ulisse Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.

About Us

We are technology leaders in distribuited and connected diagnostics


Investors

The Ulysses Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.


14 August, 2021

Scientific publications

Impact of Full Vaccination with mRNA BNT162b2 on SARS-CoV-2 Infection: Genomic and Subgenomic Viral RNAs Detection in Nasopharyngeal Swab and Saliva of Health Care Workers


This study monitored 1898 health care workers after receiving full vaccination with the BNT162b2 mRNA vaccine. In a four-month period, only 10 workers tested positive for SARS-CoV-2, with a very low cumulative incidence (0.005%). The infections were mostly mild (60% of cases) or completely asymptomatic (40%). The study also compared the effectiveness of nasopharyngeal swabs and saliva samples in detecting the virus, finding that saliva is a viable alternative for surveillance. The results confirm the high efficacy of the vaccine, but underscore the importance of continued monitoring to identify asymptomatic carriers.

Microorganisms | 2021